Navigation Links
Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
Date:6/9/2009

WOODCLIFF LAKE, N.J., June 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping calcitonin-salmon nasal spray to the trade. Calcitonin-salmon nasal spray is a generic version of Novartis' Miacalcin(R). Annual U.S. sales of Miacalcin were approximately $112 million in 2008, according to IMS Health data.

Important information about calcitonin-salmon nasal spray

Calcitonin-salmon nasal spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years post menopause with low bone mass relative to healthy premenopausal females.

Calcitonin-salmon nasal spray should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated.

Because Calcitonin is a polypeptide, the possibility of a systemic allergic reaction exists.

Please read full prescribing information available at www.parpharm.com/products.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
2. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
3. Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference
4. Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications
7. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
8. Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs
9. Isis Pharmaceuticals to Present at Goldman Sachs 30th Annual Global Healthcare Conference
10. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
11. ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Little Rock, AR (PRWEB) , ... March 27, 2017 , ... ... the CMSA National Board of Directors on June 30, 2017. CMSA’s membership has ... board. In addition to our current Military Advisory position, a new VA Advisory position ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a ... the recent RNA methylation “gold rush” with their established portfolio of optimized assay ... of N6-methyladenosine, or m6A , RNA methylation has received a new burst ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office accelerates and ... Capital has added 10 new sales professionals over the past 6 months and is ... additional new hires over the course of 2017. , “This new office is ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/25/2017)... ... 2017 , ... Norland at Swissray is pleased to announce the release of the ... ELITE DXA has an active scan window, which is more than double that of existing ... scan area could not undergo an accurate total body bone density or body composition study. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Cota ... for value-based precision medicine, today announced the ... Novartis Pharmaceuticals Corporation to help improve clinical ... As part of this agreement, ... collaboration entered into January 2016, teams from ...
(Date:3/27/2017)... , March 27, 2017 Arena Pharmaceuticals, ... focused on developing novel, small molecule drugs across multiple therapeutic ... and Chief Executive Officer, will present a corporate update at ... at 3:40pm ET.  The conference will take place April 4-5, ... New York , NY.  A ...
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
Breaking Medicine Technology: